Comment on "A non-interacting low-mass black hole -- giant star binary system"

Thompson et al. (Reports, 1 November 2019, p. 637, Science) interpreted the unseen companion of the red giant star 2MASS J05215658+4359220 as most likely a black hole. We argue that if the red giant is about one solar mass, its companion can be a close binary consisting of two main-sequence stars. This would explain why no X-ray emission is detected from the system.Comment: 3 pages, Author version of Technical Comment published in Science on 8 May, 202

Constraints on Type Ib/c and GRB Progenitors

Although there is strong support for the collapsar engine as the power source of long-duration gamma-ray bursts (GRBs), we still do not definitively know the progenitor of these explosions. Here we review the current set of progenitor scenarios for long-duration GRBs and the observational constraints on these scenarios. Examining these, we find that single-star models cannot be the only progenitor for long-duration GRBs. Several binary progenitors can match the solid observational constraints and also have the potential to match the trends we are currently seeing in the observations. Type Ib/c supernovae are also likely to be produced primarily in binaries; we discuss the relationship between the progenitors of these explosions and those of the long-duration GRBs.Comment: 36 pages, 6 figure

Implementation of Novel Molecular Biomarkers for Non-small Cell Lung Cancer in the Netherlands:How to Deal With Increasing Complexity

The diagnostic landscape of non-small cell lung cancer (NSCLC) is changing rapidly with the availability of novel treatments. Despite high-level healthcare in the Netherlands, not all patients with NSCLC are tested with the currently relevant predictive tumor markers that are necessary for optimal decision-making for today's available targeted or immunotherapy. An expert workshop on the molecular diagnosis of NSCLC involving pulmonary oncologists, clinical chemists, pathologists, and clinical scientists in molecular pathology was held in the Netherlands on December 10, 2018. The aims of the workshop were to facilitate cross-disciplinary discussions regarding standards of practice, and address recent developments and associated challenges that impact future practice. This paper presents a summary of the discussions and consensus opinions of the workshop participants on the initial challenges of harmonization of the detection and clinical use of predictive markers of NSCLC. A key theme identified was the need for broader and active participation of all stakeholders involved in molecular diagnostic services for NSCLC, including healthcare professionals across all disciplines, the hospitals and clinics involved in service delivery, healthcare insurers, and industry groups involved in diagnostic and treatment innovations. Such collaboration is essential to integrate different technologies into molecular diagnostics practice, to increase nationwide patient access to novel technologies, and to ensure consensus-preferred biomarkers are tested

The NANOGrav Nine-year Data Set:Astrometric Measurements of 37 Millisecond Pulsars

Using the nine-year radio-pulsar timing data set from the North American Nanohertz Observatory for Gravitational Waves (NANOGrav), collected at Arecibo Observatory and the Green Bank Telescope, we have measured the positions, proper motions, and parallaxes for 37 millisecond pulsars. We report twelve significant parallax measurements and distance measurements, and eighteen lower limits on distance. We compare these measurements to distances predicted by the NE2001 interstellar electron density model and find them to be in general agreement. We use measured orbital-decay rates and spin-down rates to confirm two of the parallax distances and to place distance upper limits on other sources; these distance limits agree with the parallax distances with one exception, PSR. J1024-0719, which we discuss at length. Using the proper motions of the 37 NANOGrav pulsars in combination with other published measurements, we calculate the velocity dispersion of the millisecond pulsar population in Galactocentric coordinates. We find the radial, azimuthal, and perpendicular dispersions to be 46, 40, and 24 km s(-1), respectively, in a model that allows for high-velocity outliers; or 81, 58, and 62 km s(-1) for the full population. These velocity dispersions are far smaller than those of the canonical pulsar population, and are similar to older Galactic disk populations. This suggests that millisecond pulsar velocities are largely attributable to their being an old population rather than being artifacts of their birth and evolution as neutron star binary systems. The components of these velocity dispersions follow similar proportions to other Galactic populations, suggesting that our results are not biased by selection effects

Einstein@Home discovery of a Double-Neutron Star Binary in the PALFA Survey

We report here the Einstein@Home discovery of PSR J1913+1102, a 27.3 ms pulsar found in data from the ongoing Arecibo PALFA pulsar survey. The pulsar is in a 4.95 hr double neutron star (DNS) system with an eccentricity of 0.089. From radio timing with the Arecibo 305 m telescope, we measure the rate of advance of periastron to be $\dot{\omega }=5.632(18)$° yr−1. Assuming general relativity accurately models the orbital motion, this corresponds to a total system mass of M tot =  2.875(14) ${M}_{\odot }$, similar to the mass of the most massive DNS known to date, B1913+16, but with a much smaller eccentricity. The small eccentricity indicates that the second-formed neutron star (NS) (the companion of PSR J1913+1102) was born in a supernova with a very small associated kick and mass loss. In that case, this companion is likely, by analogy with other systems, to be a light (~1.2 ${M}_{\odot }$) NS; the system would then be highly asymmetric. A search for radio pulsations from the companion yielded no plausible detections, so we cannot yet confirm this mass asymmetry. By the end of 2016, timing observations should permit the detection of two additional post-Keplerian parameters: the Einstein delay (γ), which will enable precise mass measurements and a verification of the possible mass asymmetry of the system, and the orbital decay due to the emission of gravitational waves (${\dot{P}}_{b}$), which will allow another test of the radiative properties of gravity. The latter effect will cause the system to coalesce in ~0.5 Gyr

Emergent complex neural dynamics

A large repertoire of spatiotemporal activity patterns in the brain is the basis for adaptive behaviour. Understanding the mechanism by which the brain's hundred billion neurons and hundred trillion synapses manage to produce such a range of cortical configurations in a flexible manner remains a fundamental problem in neuroscience. One plausible solution is the involvement of universal mechanisms of emergent complex phenomena evident in dynamical systems poised near a critical point of a second-order phase transition. We review recent theoretical and empirical results supporting the notion that the brain is naturally poised near criticality, as well as its implications for better understanding of the brain

Detection and localization of early- and late-stage cancers using platelet RNA

Cancer patients benefit from early tumor detection since treatment outcomes are more favorable for less advanced cancers. Platelets are involved in cancer progression and are considered a promising biosource for cancer detection, as they alter their RNA content upon local and systemic cues. We show that tumor-educated platelet (TEP) RNA-based blood tests enable the detection of 18 cancer types. With 99% specificity in asymptomatic controls, thromboSeq correctly detected the presence of cancer in two-thirds of 1,096 blood samples from stage I–IV cancer patients and in half of 352 stage I–III tumors. Symptomatic controls, including inflammatory and cardiovascular diseases, and benign tumors had increased false-positive test results with an average specificity of 78%. Moreover, thromboSeq determined the tumor site of origin in five different tumor types correctly in over 80% of the cancer patients. These results highlight the potential properties of TEP-derived RNA panels to supplement current approaches for blood-based cancer screening

Immunoglobulin, glucocorticoid, or combination therapy for multisystem inflammatory syndrome in children: a propensity-weighted cohort study

Background Multisystem inflammatory syndrome in children (MIS-C), a hyperinflammatory condition associated with SARS-CoV-2 infection, has emerged as a serious illness in children worldwide. Immunoglobulin or glucocorticoids, or both, are currently recommended treatments. Methods The Best Available Treatment Study evaluated immunomodulatory treatments for MIS-C in an international observational cohort. Analysis of the first 614 patients was previously reported. In this propensity-weighted cohort study, clinical and outcome data from children with suspected or proven MIS-C were collected onto a web-based Research Electronic Data Capture database. After excluding neonates and incomplete or duplicate records, inverse probability weighting was used to compare primary treatments with intravenous immunoglobulin, intravenous immunoglobulin plus glucocorticoids, or glucocorticoids alone, using intravenous immunoglobulin as the reference treatment. Primary outcomes were a composite of inotropic or ventilator support from the second day after treatment initiation, or death, and time to improvement on an ordinal clinical severity scale. Secondary outcomes included treatment escalation, clinical deterioration, fever, and coronary artery aneurysm occurrence and resolution. This study is registered with the ISRCTN registry, ISRCTN69546370. Findings We enrolled 2101 children (aged 0 months to 19 years) with clinically diagnosed MIS-C from 39 countries between June 14, 2020, and April 25, 2022, and, following exclusions, 2009 patients were included for analysis (median age 8·0 years [IQR 4·2–11·4], 1191 [59·3%] male and 818 [40·7%] female, and 825 [41·1%] White). 680 (33·8%) patients received primary treatment with intravenous immunoglobulin, 698 (34·7%) with intravenous immunoglobulin plus glucocorticoids, 487 (24·2%) with glucocorticoids alone; 59 (2·9%) patients received other combinations, including biologicals, and 85 (4·2%) patients received no immunomodulators. There were no significant differences between treatments for primary outcomes for the 1586 patients with complete baseline and outcome data that were considered for primary analysis. Adjusted odds ratios for ventilation, inotropic support, or death were 1·09 (95% CI 0·75–1·58; corrected p value=1·00) for intravenous immunoglobulin plus glucocorticoids and 0·93 (0·58–1·47; corrected p value=1·00) for glucocorticoids alone, versus intravenous immunoglobulin alone. Adjusted average hazard ratios for time to improvement were 1·04 (95% CI 0·91–1·20; corrected p value=1·00) for intravenous immunoglobulin plus glucocorticoids, and 0·84 (0·70–1·00; corrected p value=0·22) for glucocorticoids alone, versus intravenous immunoglobulin alone. Treatment escalation was less frequent for intravenous immunoglobulin plus glucocorticoids (OR 0·15 [95% CI 0·11–0·20]; p<0·0001) and glucocorticoids alone (0·68 [0·50–0·93]; p=0·014) versus intravenous immunoglobulin alone. Persistent fever (from day 2 onward) was less common with intravenous immunoglobulin plus glucocorticoids compared with either intravenous immunoglobulin alone (OR 0·50 [95% CI 0·38–0·67]; p<0·0001) or glucocorticoids alone (0·63 [0·45–0·88]; p=0·0058). Coronary artery aneurysm occurrence and resolution did not differ significantly between treatment groups. Interpretation Recovery rates, including occurrence and resolution of coronary artery aneurysms, were similar for primary treatment with intravenous immunoglobulin when compared to glucocorticoids or intravenous immunoglobulin plus glucocorticoids. Initial treatment with glucocorticoids appears to be a safe alternative to immunoglobulin or combined therapy, and might be advantageous in view of the cost and limited availability of intravenous immunoglobulin in many countries. Funding Imperial College London, the European Union's Horizon 2020, Wellcome Trust, the Medical Research Foundation, UK National Institute for Health and Care Research, and National Institutes of Health